Weekly epirubicin in the treatment of gestational breast cancer (GBC)

Fedro A. Peccatori, Hatem A. Azim, Giovanna Scarfone, Angiolo Gadducci, Cristina Bonazzi, Oreste Gentilini, Viviana Galimberti, Mattia Intra, Marzia Locatelli, Barbara Acaia, Piero Rossi, Saverio Cinieri, Liliana Calabrese, Aron Goldhirsch

Research output: Contribution to journalArticlepeer-review


Background GBC is a rare disease and chemotherapy in this setting lacks a standardized approach. Patients and Methods Patients 16-30 weeks pregnant with locally advanced/metastatic disease or with high risk of recurrence after surgery were evaluated. Results Twenty patients received weekly epirubicin 35 mg/m2. Median maternal age was 37 years (23-42). Median gestational age at chemotherapy was 19 weeks. Thirteen patients were treated after surgery while 7 had locally advanced tumours of which one had liver metastases. Mean total epirubicin dose was 420 mg/m2 with a median number of 12 administrations (4-16). No grade 3-4 toxicities were observed. No foetal adverse events were observed except 1 premature delivery at 28 weeks. Births were induced by caesarean section in 12 patients at a median gestational age of 35 weeks. No malformations were reported except 1 newborn with polycystic kidney. At a median age of 2 years, neurological, cardiological and immunological development was normal in all children as reported by their parents. In 7/20 patients with evaluable disease, five had an objective response. At a median follow-up of 38 months, 17 patients are alive; 14 are disease free. Conclusions Weekly epirubicin appears safe and effective with low foetal toxicity and could be considered in GBC.

Original languageEnglish
Pages (from-to)591-594
Number of pages4
JournalBreast Cancer Research and Treatment
Issue number3
Publication statusPublished - Jun 2009


  • Breast cancer
  • Chemotherapy
  • Epirubicin
  • Foetus
  • Pregnancy
  • Safety

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Weekly epirubicin in the treatment of gestational breast cancer (GBC)'. Together they form a unique fingerprint.

Cite this